

February 14, 2025

To,  
**Dy. General Manager**  
Department of Corporate Services,  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai – 400 001

To,  
**The Manager – Listing,**  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sir,

**Sub: Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)**

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

*Encl: As above*

**Glenmark Pharmaceuticals Limited**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

## **Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)**

**Mahwah, New Jersey, February 14, 2025** – Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch<sup>1</sup> of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL). Glenmark’s Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan<sup>®2</sup> Ophthalmic Solution, 0.005% of Upjohn US 2 LLC.

According to IQVIA<sup>TM</sup> sales data for the 12-month period ending December 2024, the Xalatan<sup>®</sup> Ophthalmic Solution, 0.005% market<sup>3</sup> achieved annual sales of approximately \$113.5 million\*.

**Commenting on the launch, Marc Kikuchi, President & Business Head, North America said,** “We are excited to announce the launch of our 4<sup>th</sup> ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel. This addition highlights our commitment to meeting market needs and providing quality solutions for our customers.”

---End---

### **About Glenmark Pharmaceuticals Ltd.**

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit [www.glenmarkpharma.com](http://www.glenmarkpharma.com). You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark\_pharma).

### **For more information, please contact**

Udaykumar Murthy | [corpcomm@glenmarkpharma.com](mailto:corpcomm@glenmarkpharma.com) | +91 9960377617

### **References:**

<sup>1</sup>Glenmark’s Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is only approved for the indication(s) listed in Glenmark’s approved label.

<sup>2</sup>All brand names and trademarks are the property of their respective owners.

<sup>3</sup>Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.

\*IQVIATM National Sales Perspectives: Retail & Non-Retail, December 2024